Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.70 |
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16199093 | 0.99 | GSK3A (0.72) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199091 | 0.99 | GSK3A (0.72) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9977673 | 0.99 | GSK3A (0.72) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9940696 | 0.99 | GSK3A (0.72) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199081 | 0.99 | GSK3A (0.72) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199033 | 0.99 | GSK3A (0.72) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL15401189 | 0.98 | GSK3A (0.70) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199060 | 0.96 | GSK3A (0.68) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199107 | 0.96 | GSK3A (0.68) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9977662 | 0.96 | GSK3A (0.68) | GSK3AGSK3BFLT3JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871774-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | GSK3A 997/4885GSK3B 924/4885FLT3 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.